The rna targeting small molecules therapeutics market size has grown strongly in recent years. It will grow from $2.93 billion in 2025 to $3.1 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to limited efficacy of protein-targeted drugs, growth in genomic research funding, increasing prevalence of cancer and genetic disorders, early success of rna-based therapies, expansion of academic-industry collaborations.
The rna targeting small molecules therapeutics market size is expected to see rapid growth in the next few years. It will grow to $4.84 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advances in rna structure prediction, increasing demand for precision therapeutics, rising biotech investments in small molecules, regulatory support for novel rna drugs, growing pipeline of rna-targeting clinical trials. Major trends in the forecast period include expansion of rna-targeted drug pipelines, growing focus on undruggable disease targets, increased collaboration between pharma and biotech firms, advances in rna structural biology and chemistry, rising investment in rare and genetic disease therapies.
The growing number of cancer cases is anticipated to drive the expansion of the RNA-targeting small molecule therapeutics market in the coming years. Cancer refers to a group of diseases that can arise in almost any organ or tissue when abnormal cells grow uncontrollably, breach normal boundaries, and spread to other organs or infiltrate surrounding tissues. RNA-targeting small molecules are developed and studied to selectively act on RNA molecules linked to cancer, making them a promising treatment approach. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases reported in 2022. As a result, the rising burden of cancer is fueling the growth of the RNA-targeting small molecule therapeutics market.
The increasing prevalence of genetic disorders is expected to support the growth of the RNA-targeting small-molecule therapeutics market in the years ahead. Genetic disorders are diseases caused by defects or mutations in an individual’s genetic material, including DNA or chromosomes. RNA-targeting small-molecule therapeutics represent a rapidly evolving area with significant potential for treating such conditions. Certain genetic disorders are associated with harmful expansions of repeated RNA sequences, and small molecules can either stabilize or disrupt these expansions, potentially reducing their negative effects. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the number of people living with cystic fibrosis in the UK increased from 11,148 in 2022 to 11,318 in 2023. Consequently, the rising incidence of genetic disorders is contributing to the growth of the RNA-targeting small-molecule therapeutics market.
Leading companies operating in the RNA-targeting small molecule therapeutics market are emphasizing strategic partnerships to strengthen the discovery and development of new therapies. In this context, strategic partnerships involve collaborations between organizations to pool expertise, share data, and accelerate the development of innovative RNA-targeting small molecules. For instance in April 2024, Ipsen, a France-based biopharmaceutical company, partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company specializing in RNA-targeting small molecule therapeutics. Through this partnership, Ipsen aims to develop RNA-targeting small molecule therapies for rare neurological diseases by integrating diverse datasets to identify and advance molecules capable of modulating RNA.
Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics.
North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna targeting small molecules therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created cost and supply chain challenges for the rna targeting small molecules therapeutics market by increasing prices of specialized chemicals, reagents, and advanced laboratory instruments used in rna research and drug development. These impacts are most pronounced in drug discovery and oncology research segments, as well as in regions such as asia-pacific and europe that rely heavily on cross-border sourcing of raw materials and analytical equipment. Pharmaceutical and biotechnology companies face higher operational costs and longer development timelines due to import duties on critical inputs. However, tariffs are also encouraging localized manufacturing, regional supplier development, and strategic partnerships, which may strengthen domestic rna therapeutics ecosystems over the long term.
The rna targeting small molecules therapeutics market research report is one of a series of new reports that provides rna targeting small molecules therapeutics market statistics, including rna targeting small molecules therapeutics industry global market size, regional shares, competitors with a rna targeting small molecules therapeutics market share, detailed rna targeting small molecules therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the rna targeting small molecules therapeutics industry. This rna targeting small molecules therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
RNA-targeting small molecule therapeutics are small-molecule drugs designed to selectively bind to RNA molecules and alter their function or stability. These therapies address diseases by using small molecules to target RNA sequences involved in disease development.
The key offerings within RNA-targeting small molecule therapeutics include messenger RNA (mRNA) translation modulators, RNA splicing modifiers, direct RNA targeting agents, and others. mRNA translation modulators are compounds that affect protein production by changing the efficiency or speed of mRNA translation. These therapeutics are used for treating conditions such as lung fibrosis, cancer, neurodegenerative disorders, autoimmune and inflammatory diseases, among others, with applications spanning drug discovery, oncology research, and disease identification across hospitals, research institutes, pharmaceutical companies, biotechnology firms, and other end users.
The RNA-targeting small molecule therapeutics market consists of sales of nusinersen, inotersen, givosiran, and patisiran. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The rna targeting small molecules therapeutics market size is expected to see rapid growth in the next few years. It will grow to $4.84 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advances in rna structure prediction, increasing demand for precision therapeutics, rising biotech investments in small molecules, regulatory support for novel rna drugs, growing pipeline of rna-targeting clinical trials. Major trends in the forecast period include expansion of rna-targeted drug pipelines, growing focus on undruggable disease targets, increased collaboration between pharma and biotech firms, advances in rna structural biology and chemistry, rising investment in rare and genetic disease therapies.
The growing number of cancer cases is anticipated to drive the expansion of the RNA-targeting small molecule therapeutics market in the coming years. Cancer refers to a group of diseases that can arise in almost any organ or tissue when abnormal cells grow uncontrollably, breach normal boundaries, and spread to other organs or infiltrate surrounding tissues. RNA-targeting small molecules are developed and studied to selectively act on RNA molecules linked to cancer, making them a promising treatment approach. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared to the estimated 20 million cases reported in 2022. As a result, the rising burden of cancer is fueling the growth of the RNA-targeting small molecule therapeutics market.
The increasing prevalence of genetic disorders is expected to support the growth of the RNA-targeting small-molecule therapeutics market in the years ahead. Genetic disorders are diseases caused by defects or mutations in an individual’s genetic material, including DNA or chromosomes. RNA-targeting small-molecule therapeutics represent a rapidly evolving area with significant potential for treating such conditions. Certain genetic disorders are associated with harmful expansions of repeated RNA sequences, and small molecules can either stabilize or disrupt these expansions, potentially reducing their negative effects. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the number of people living with cystic fibrosis in the UK increased from 11,148 in 2022 to 11,318 in 2023. Consequently, the rising incidence of genetic disorders is contributing to the growth of the RNA-targeting small-molecule therapeutics market.
Leading companies operating in the RNA-targeting small molecule therapeutics market are emphasizing strategic partnerships to strengthen the discovery and development of new therapies. In this context, strategic partnerships involve collaborations between organizations to pool expertise, share data, and accelerate the development of innovative RNA-targeting small molecules. For instance in April 2024, Ipsen, a France-based biopharmaceutical company, partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company specializing in RNA-targeting small molecule therapeutics. Through this partnership, Ipsen aims to develop RNA-targeting small molecule therapies for rare neurological diseases by integrating diverse datasets to identify and advance molecules capable of modulating RNA.
Major companies operating in the rna targeting small molecules therapeutics market are F Hoffmann La Roche Ltd, Novartis AG, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Amgen Inc, Bayer AG, Vertex Pharmaceuticals Inc, PTC Therapeutics Inc, Arrakis Therapeutics, Anima Biotech Inc, Skyhawk Therapeutics Inc, Remix Therapeutics, Accent Therapeutics Inc, STORM Therapeutics Ltd, eFFECTOR Therapeutics Inc, EPICS Therapeutics, Expansion Therapeutics Inc, Ribometrix Inc, Redona Therapeutics, Eloxx Pharmaceuticals Inc, 858 Therapeutics.
North America was the largest region in the RNA targeting small molecules therapeutics market in 2025. The regions covered in the rna targeting small molecules therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna targeting small molecules therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created cost and supply chain challenges for the rna targeting small molecules therapeutics market by increasing prices of specialized chemicals, reagents, and advanced laboratory instruments used in rna research and drug development. These impacts are most pronounced in drug discovery and oncology research segments, as well as in regions such as asia-pacific and europe that rely heavily on cross-border sourcing of raw materials and analytical equipment. Pharmaceutical and biotechnology companies face higher operational costs and longer development timelines due to import duties on critical inputs. However, tariffs are also encouraging localized manufacturing, regional supplier development, and strategic partnerships, which may strengthen domestic rna therapeutics ecosystems over the long term.
The rna targeting small molecules therapeutics market research report is one of a series of new reports that provides rna targeting small molecules therapeutics market statistics, including rna targeting small molecules therapeutics industry global market size, regional shares, competitors with a rna targeting small molecules therapeutics market share, detailed rna targeting small molecules therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the rna targeting small molecules therapeutics industry. This rna targeting small molecules therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
RNA-targeting small molecule therapeutics are small-molecule drugs designed to selectively bind to RNA molecules and alter their function or stability. These therapies address diseases by using small molecules to target RNA sequences involved in disease development.
The key offerings within RNA-targeting small molecule therapeutics include messenger RNA (mRNA) translation modulators, RNA splicing modifiers, direct RNA targeting agents, and others. mRNA translation modulators are compounds that affect protein production by changing the efficiency or speed of mRNA translation. These therapeutics are used for treating conditions such as lung fibrosis, cancer, neurodegenerative disorders, autoimmune and inflammatory diseases, among others, with applications spanning drug discovery, oncology research, and disease identification across hospitals, research institutes, pharmaceutical companies, biotechnology firms, and other end users.
The RNA-targeting small molecule therapeutics market consists of sales of nusinersen, inotersen, givosiran, and patisiran. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. RNA Targeting Small Molecules Therapeutics Market Characteristics
3. RNA Targeting Small Molecules Therapeutics Market Supply Chain Analysis
4. Global RNA Targeting Small Molecules Therapeutics Market Trends and Strategies
5. RNA Targeting Small Molecules Therapeutics Market Analysis of End Use Industries
7. Global RNA Targeting Small Molecules Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global RNA Targeting Small Molecules Therapeutics Total Addressable Market (TAM) Analysis for the Market
9. RNA Targeting Small Molecules Therapeutics Market Segmentation
10. RNA Targeting Small Molecules Therapeutics Market Regional and Country Analysis
11. Asia-Pacific RNA Targeting Small Molecules Therapeutics Market
12. China RNA Targeting Small Molecules Therapeutics Market
13. India RNA Targeting Small Molecules Therapeutics Market
14. Japan RNA Targeting Small Molecules Therapeutics Market
15. Australia RNA Targeting Small Molecules Therapeutics Market
16. Indonesia RNA Targeting Small Molecules Therapeutics Market
17. South Korea RNA Targeting Small Molecules Therapeutics Market
18. Taiwan RNA Targeting Small Molecules Therapeutics Market
19. South East Asia RNA Targeting Small Molecules Therapeutics Market
20. Western Europe RNA Targeting Small Molecules Therapeutics Market
21. UK RNA Targeting Small Molecules Therapeutics Market
22. Germany RNA Targeting Small Molecules Therapeutics Market
23. France RNA Targeting Small Molecules Therapeutics Market
24. Italy RNA Targeting Small Molecules Therapeutics Market
25. Spain RNA Targeting Small Molecules Therapeutics Market
26. Eastern Europe RNA Targeting Small Molecules Therapeutics Market
27. Russia RNA Targeting Small Molecules Therapeutics Market
28. North America RNA Targeting Small Molecules Therapeutics Market
29. USA RNA Targeting Small Molecules Therapeutics Market
30. Canada RNA Targeting Small Molecules Therapeutics Market
31. South America RNA Targeting Small Molecules Therapeutics Market
32. Brazil RNA Targeting Small Molecules Therapeutics Market
33. Middle East RNA Targeting Small Molecules Therapeutics Market
34. Africa RNA Targeting Small Molecules Therapeutics Market
36. RNA Targeting Small Molecules Therapeutics Market Competitive Landscape and Company Profiles
37. RNA Targeting Small Molecules Therapeutics Market Other Major and Innovative Companies
40. RNA Targeting Small Molecules Therapeutics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
RNA Targeting Small Molecules Therapeutics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses rna targeting small molecules therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rna targeting small molecules therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rna targeting small molecules therapeutics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators; RNA (Ribonucleic Acid) Splicing Modification; Direct RNA (Ribonucleic Acid) Targeting; Other Offerings2) By Therapeutic Indication: Lung Fibrosis; Cancer; Neurodegenerative Diseases; Autoimmune; Inflammatory; Other Therapeutic Indications
3) By End User: Hospitals; Research Laboratories; Pharmaceutical And Biotechnology Companies; Other End-Users
Companies Mentioned: F Hoffmann La Roche Ltd; Novartis AG; Sanofi SA; AstraZeneca plc; Eli Lilly and Company; Amgen Inc; Bayer AG; Vertex Pharmaceuticals Inc; PTC Therapeutics Inc; Arrakis Therapeutics; Anima Biotech Inc; Skyhawk Therapeutics Inc; Remix Therapeutics; Accent Therapeutics Inc; STORM Therapeutics Ltd; eFFECTOR Therapeutics Inc; EPICS Therapeutics; Expansion Therapeutics Inc; Ribometrix Inc; Redona Therapeutics; Eloxx Pharmaceuticals Inc; 858 Therapeutics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this RNA Targeting Small Molecules Therapeutics market report include:- F Hoffmann La Roche Ltd
- Novartis AG
- Sanofi SA
- AstraZeneca plc
- Eli Lilly and Company
- Amgen Inc
- Bayer AG
- Vertex Pharmaceuticals Inc
- PTC Therapeutics Inc
- Arrakis Therapeutics
- Anima Biotech Inc
- Skyhawk Therapeutics Inc
- Remix Therapeutics
- Accent Therapeutics Inc
- STORM Therapeutics Ltd
- eFFECTOR Therapeutics Inc
- EPICS Therapeutics
- Expansion Therapeutics Inc
- Ribometrix Inc
- Redona Therapeutics
- Eloxx Pharmaceuticals Inc
- 858 Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.1 Billion |
| Forecasted Market Value ( USD | $ 4.84 Billion |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
